Gottfried E. Konecny

University of California, Los Angeles — United States

Medicine · Health Sciences

58h-index20.4kcitations408works3.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(182), PARP inhibition in cancer therapy(95), Cancer Genomics and Diagnostics(48), Endometrial and Cervical Cancer Treatments(42), HER2/EGFR in Cancer Research(40)

Publications403 total

Ocular Toxic Effects During Mirvetuximab Soravtansine Therapy
JAMA Oncology·2026Open Access
Trastuzumab deruxtecan and the evolving role of human epidermal growth factor receptor 2–targeted antibody–drug conjugates in breast and ovarian cancer
Current Opinion in Obstetrics & Gynecology·2025
Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Figure 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Supplemental Table 4 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
2025Open Access
Figure 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Table 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Table 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Figure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Supplemental Table 3 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
2025Open Access
Table 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Supplementary Methods 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
Supplementary Figures S1-S13 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
2025Open Access
RINATABART SESUTECAN MONOTHERAPY IN PATIENTS WITH ADVANCED ENDOMETRIAL CANCER: PART F OF THE PHASE 1/2 RAINFOL™-01 STUDY
International Journal of Gynecological Cancer·2025
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma
2025Open Access
Beyond <i>BRCA</i> deficiency: Clinical and molecular predictors of survival in patients with <i>BRCA</i> -deficient tubo-ovarian high-grade serous carcinoma
2025Open Access
Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol
Gynecologic Oncology·2025Open Access
Efficacy and safety of abemaciclib, a CDK4/6 inhibitor, combined with hormone therapy in selected patients with recurrent ovarian or endometrial cancer: An open-label phase II study
Gynecologic Oncology·2025
Racial disparity in the utilization of immunotherapy for Food and Drug Administration-approved indications in recurrent endometrial cancer
Gynecologic Oncology·2025
Impact of treatment-emergent ocular events on health-related quality of life in patients with folate receptor alpha-positive platinum-resistant ovarian cancer treated with mirvetuximab soravtansine: Results from the phase III MIRASOL study
Gynecologic Oncology·2025
page 1 of 21Next →

Frequent Co-authors

Michael Untch(15), Dennis J. Slamon(11), Boris Winterhoff(11), Peter A. Fasching(9), Kimberly R. Kalli(9), Amit M. Oza(8), Ana Oaknin(8), Gϋnter von Minckwitz(7), David M. O’Malley(7), Iain A. McNeish(7), Nadia Harbeck(7), Judy Dering(7), Sibylle Loibl(6), Robert L. Coleman(6), Alexandra Léary(6), Elizabeth M. Swisher(6), Clare L. Scott(6), Heidi Giordano(6), Rebecca Kristeleit(6), Mark D. Pegram(6)